SB Capital Management Inc Invests $11.54 Million in Capricor Therapeutics, Inc. $CAPR

SB Capital Management Inc purchased a new position in Capricor Therapeutics, Inc. (NASDAQ:CAPR) in the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The firm purchased 400,001 shares of the biotechnology company’s stock, valued at approximately $11,544,000. Capricor Therapeutics makes up about 4.2% of SB Capital Management Inc’s investment portfolio, making the stock its 5th largest holding. SB Capital Management Inc owned 0.87% of Capricor Therapeutics at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Suvretta Capital Management LLC bought a new position in Capricor Therapeutics during the 4th quarter worth approximately $51,533,000. Tang Capital Management LLC bought a new stake in shares of Capricor Therapeutics in the 4th quarter valued at approximately $49,062,000. RA Capital Management L.P. bought a new stake in shares of Capricor Therapeutics in the 4th quarter valued at approximately $43,516,000. Darwin Global Management Ltd. acquired a new stake in shares of Capricor Therapeutics during the 4th quarter valued at approximately $23,168,000. Finally, Vanguard Group Inc. raised its position in shares of Capricor Therapeutics by 16.1% during the 4th quarter. Vanguard Group Inc. now owns 2,561,880 shares of the biotechnology company’s stock valued at $73,936,000 after acquiring an additional 355,161 shares in the last quarter. 21.68% of the stock is owned by institutional investors.

Insider Activity

In other Capricor Therapeutics news, Director Karimah Es Sabar sold 7,529 shares of the firm’s stock in a transaction that occurred on Thursday, April 2nd. The shares were sold at an average price of $32.00, for a total value of $240,928.00. Following the sale, the director owned 7,529 shares in the company, valued at approximately $240,928. This trade represents a 50.00% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Anthony Bergmann sold 25,000 shares of the firm’s stock in a transaction that occurred on Friday, May 1st. The shares were sold at an average price of $31.70, for a total transaction of $792,500.00. Following the completion of the sale, the chief financial officer owned 8,223 shares in the company, valued at $260,669.10. The trade was a 75.25% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders sold 172,529 shares of company stock worth $5,302,440. 9.20% of the stock is currently owned by insiders.

Capricor Therapeutics Price Performance

NASDAQ:CAPR opened at $28.38 on Friday. The firm has a market capitalization of $1.64 billion, a P/E ratio of -12.23 and a beta of 0.39. The business has a 50 day simple moving average of $30.50 and a 200 day simple moving average of $28.06. Capricor Therapeutics, Inc. has a 12-month low of $4.30 and a 12-month high of $40.37.

Capricor Therapeutics (NASDAQ:CAPR) last issued its earnings results on Tuesday, May 12th. The biotechnology company reported ($0.59) earnings per share for the quarter, missing the consensus estimate of ($0.55) by ($0.04). Research analysts anticipate that Capricor Therapeutics, Inc. will post -0.75 EPS for the current fiscal year.

Analyst Ratings Changes

Several brokerages recently issued reports on CAPR. B. Riley Financial raised their price objective on Capricor Therapeutics from $50.00 to $63.00 and gave the stock a “buy” rating in a research note on Friday, March 13th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Capricor Therapeutics in a research note on Monday. Cantor Fitzgerald set a $62.00 target price on shares of Capricor Therapeutics and gave the stock an “overweight” rating in a report on Friday, March 13th. Roth Mkm restated a “buy” rating and issued a $38.00 price target on shares of Capricor Therapeutics in a research report on Friday, May 15th. Finally, Piper Sandler reaffirmed an “overweight” rating and issued a $58.00 price target (up from $45.00) on shares of Capricor Therapeutics in a report on Friday, March 13th. Nine analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $48.36.

Capricor Therapeutics Company Profile

Capricor Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of cell and exosome-based therapeutics for cardiovascular and rare diseases. Headquartered in Beverly Hills, California, the company leverages proprietary cardiosphere-derived cell (CDC) technology to address conditions characterized by inflammation, fibrosis, and tissue degeneration. Since its founding, Capricor has advanced its lead candidate through multiple clinical trials and has built a pipeline that spans both cell therapy and extracellular vesicle (exosome) platforms.

The company’s leading product candidate, CAP-1002, comprises allogeneic CDCs and is being evaluated in indications such as Duchenne muscular dystrophy (DMD) and COVID-19-related heart injury.